What Doctors Say - Across Europe
Dermatologists have been using and researching Soratinex (known on the Continent as ‘Dr Michaels’) for more than a decade. An analysis of eight studies involving 2,050 patients found that 85 per cent enjoyed an improvement in their symptoms of between 51 and 100 per cent. Here, some leading dermatologists describe their experiences working with Soratinex.
Professor Uwe Wollina
23th Dermato-Oncological Day (Jena - 26. Oktober, 2019)
Symposium "Diagnostics and Therapy News" (Dresden - 30.11.2019)
Head of the Department of Dermatology at the Academic Teaching Hospital, Dresden, Professor Wollina completed Germany's first clinical trials of Soratinex at the end of 2017. In his trial, all patients achieved a reduction in their symptoms of at least 50 per cent. By week 8, 94.4 per cent of patients on the trial declared themselves 'satisfied' or 'very satisfied' with the results.
He says: ‘The treatment is self-usable by the patient, so that provides more autonomy and it is proving very, very safe – the only side effect we have seen is a mild stinging sensation.
‘The results are comparable with the most successful corticosteroids and are miles ahead of any other non-steroidal topical treatment on the market. And the most interesting fact is that while steroid treatments can produce good results in three to four weeks, we are seeing the best improvements with Soratinex in the first two weeks.’
His relevant research can be found here: https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=27498651
His full body of research here: https://www.ncbi.nlm.nih.gov/pmc/?term=wollina+uwe
Professor Jana Hercogová
Former President of the European Academy of Dermatology, currently Chairwoman of the Dermatovenereology Department of Charles University, Prague, has had experience of Soratinex dating back more than 10 years.
She says: ‘When FRANKL Pharma first asked me to try the treatment, I was sceptical but eventually I tried it on a child with proriasis of the scalp. Everything else had failed, but this cleared it up. Then I tried it on another patient, then another and the results were very encouraging.
‘Between 2005 and 2008, 203 patients in 10 hospitals across the Czech Republic were treated with [Soratinex] and we saw improvements in around 80 per cent of all patients. I would not use it in severe cases where most of the body is covered in lesions because it is a three-part treatment and this makes it impractical.
‘But in cases of plaque psoriasis with symptoms ranging from mild to moderate – which is about 80 per cent of all cases – then I would recommend Soratinex. It is unbelievably effective.’
Her relevant research can be found here: https://www.ncbi.nlm.nih.gov/pubmed/?term=hercegova+j+dr+michaels
Full body of research here: https://www.ncbi.nlm.nih.gov/pubmed/?term=hercogova+j
Professor Torello Lotti
Professor and Chair of Dermatology at the University of Rome G.Marconi, has collaborated in studies of Soratinex with clinicians and academics from Italy, Austria, Hungary, the Czech Republic, Romania, Russia and other countries for more than 15 years.
He says: ‘I am pleased that the UK clinical trial conducted by Professor Chu and Dr Brazzini have concluded with results very similar to these previous studies. We have repeatedly found that Soratinex performs at least as well as the established and more powerul systemic treatments, yet because it contains no corticosteroids there is no risk of side effects, which means it can also be used to treat children and pregnant women.
‘The effects of psoriasis can be very debilitating. Those affected think that they have the choice of either using powerful and potent medication every day that can act as a poison over time, or of not using them and suffering.
‘I think now we have something that can work for them but without the side-effects.’
His relevant research can be found here: https://www.ncbi.nlm.nih.gov/m/pubmed/?term=lotti+t+%2C+tirant+m+
Full body of research here: https://www.ncbi.nlm.nih.gov/m/pubmed/?term=lotti+t+